BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 34468080)

  • 1. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
    Anderson K; Nelson CH; Gong Q; Alani M; Tarnowski T; Othman AA
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):235-245. PubMed ID: 34468080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
    Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
    Caro L; Prueksaritanont T; Fandozzi CM; Feng HP; Guo Z; Wolford D; Panebianco D; Fraser IP; Levine V; Swearingen D; Butterton JR; Iwamoto M; Yeh WW
    Clin Drug Investig; 2021 Feb; 41(2):133-147. PubMed ID: 33527237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects.
    Maekawa Y; Furuie H; Kato M; Myobatake Y; Kamiyama E; Watanabe A; Shiosakai K; Taguchi T; Bass R; Zhou J; Dishy V; Warren V; Vashi V; Ishizuka H
    Clin Drug Investig; 2019 Oct; 39(10):967-978. PubMed ID: 31321631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.
    Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Quinson AM; Haertter S
    J Clin Pharmacol; 2017 Oct; 57(10):1305-1314. PubMed ID: 28513969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
    Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects.
    Hsueh CH; Anderson K; Shen G; Yun C; Qin A; Othman AA
    Clin Transl Sci; 2022 Feb; 15(2):361-370. PubMed ID: 34498807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.
    Groenendaal-van de Meent D; den Adel M; Kerbusch V; van Dijk J; Shibata T; Kato K; Schaddelee M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):486-501. PubMed ID: 35182045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects.
    Moon SJ; Jeon JY; Jang K; Yu KS; Lim Y; Kim MG
    Drug Des Devel Ther; 2019; 13():2533-2542. PubMed ID: 31440035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
    Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
    J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
    Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Martin PD; Dane AL; Schneck DW; Warwick MJ
    Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Drug-Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
    Begley R; Anderson K; Watkins TR; Weng W; Ampaw L; Qin A; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):376-383. PubMed ID: 32989920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
    Courlet P; Spaggiari D; Desfontaine V; Cavassini M; Alves Saldanha S; Buclin T; Marzolini C; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1125():121733. PubMed ID: 31374423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
    Pham PA; la Porte CJ; Lee LS; van Heeswijk R; Sabo JP; Elgadi MM; Piliero PJ; Barditch-Crovo P; Fuchs E; Flexner C; Cameron DW
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4385-92. PubMed ID: 19667285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers.
    Offman E; Davidson M; Nilsson C
    J Clin Lipidol; 2017; 11(3):739-748. PubMed ID: 28506390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
    Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
    J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.